Bereich
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
[Role of individualized dosing in oncology: are we there yet?]
Jörger M. [Role of individualized dosing in oncology: are we there yet?]. Praxis (Bern 1994) 2013; 103:33-9.
31.12.2013[Role of individualized dosing in oncology: are we there yet?]
31.12.2013Praxis (Bern 1994) 2013; 103:33-9
Jörger Markus
Ritonavir, nelfinavir, saquinavir and lopinavir induce proteotoxic stress in acute myeloid leukemia cells and sensitize them for proteasome inhibitor treatment at low micromolar drug concentrations
Kraus M, Müller-Ide H, Rückrich T, Bader J, Overkleeft H, Driessen C. Ritonavir, nelfinavir, saquinavir and lopinavir induce proteotoxic stress in acute myeloid leukemia cells and sensitize them for proteasome inhibitor treatment at low micromolar drug concentrations. Leuk Res 2013; 38:383-92.
25.12.2013Ritonavir, nelfinavir, saquinavir and lopinavir induce proteotoxic stress in acute myeloid leukemia cells and sensitize them for proteasome inhibitor treatment at low micromolar drug concentrations
25.12.2013Leuk Res 2013; 38:383-92
Kraus Marianne, Müller-Ide Hendrik, Rückrich Thomas, Bader Jürgen, Overkleeft Herman, Driessen Christoph
Activity of Cabazitaxel in Castration-resistant Prostate Cancer Progressing After Docetaxel and Next-generation Endocrine Agents
Pezaro C, de Bono J, Parker C, Dearnaley D, Bianchini D, Ferraldeschi R, Lorente D, Altavilla A, Omlin A, Attard G. Activity of Cabazitaxel in Castration-resistant Prostate Cancer Progressing After Docetaxel and Next-generation Endocrine Agents. Eur Urol 2013
17.12.2013Activity of Cabazitaxel in Castration-resistant Prostate Cancer Progressing After Docetaxel and Next-generation Endocrine Agents
17.12.2013Eur Urol 2013
Pezaro Carmel J, de Bono Johann S, Parker Christopher, Dearnaley David, Bianchini Diletta, Ferraldeschi Roberta, Lorente David, Altavilla Amelia, Omlin Aurelius, Attard Gerhardt
Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone
Gnant M, Steger G, Balic M, Ressler S, Cowens J, Storhoff J, Ferree S, Schaper C, Liu S, Fesl C, Nielsen T, Bartsch R, Fitzal F, Dubsky P, Filipits M, Greil R, Stoeger H, Rudas M, Bago-Horvath Z, Mlineritsch B, Kwasny W, Knauer M, Singer C, Jakesz R, Austrian Breast and Colorectal Cancer Study Group. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. Ann Oncol 2013; 25:339-45.
16.12.2013Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone
16.12.2013Ann Oncol 2013; 25:339-45
Gnant M, Steger G, Balic M, Ressler S, Cowens J W, Storhoff J, Ferree S, Schaper C, Liu S, Fesl C, Nielsen T O, Bartsch R, Fitzal F, Dubsky P, Filipits M, Greil R, Stoeger H, Rudas M, Bago-Horvath Z, Mlineritsch B, Kwasny W, Knauer Michael, Singer C, Jakesz R, Austrian Breast and Colorectal Cancer Study Group
Outcome of mantle cell lymphoma patients treated at a single institution over the past decade
Hitz F, Diem S, Haile S, ess s, Cerny T, Mey U. Outcome of mantle cell lymphoma patients treated at a single institution over the past decade. Hematol Oncol 2013
11.12.2013Outcome of mantle cell lymphoma patients treated at a single institution over the past decade
11.12.2013Hematol Oncol 2013
Hitz Felicitas, Diem Stefan, Haile Sarah, ess silvia, Cerny Thomas, Mey Ulrich
Symptoms of endocrine treatment and outcome in the BIG 1-98 study
Huober J, Thürlimann B, Gelber R, Colleoni M, Coates A, Goldhirsch A, Price K, Wardley A, Smith I, Láng I, Neven P, Forbes J, Bonnefoi H, Ejlertsen B, Wu J, Giobbie-Hurder A, Rabaglio M, Cole B, BIG 1-98 Collaborative and International Breast Cancer Study Groups. Symptoms of endocrine treatment and outcome in the BIG 1-98 study. Breast Cancer Res Treat 2013; 143:159-69.
05.12.2013Symptoms of endocrine treatment and outcome in the BIG 1-98 study
05.12.2013Breast Cancer Res Treat 2013; 143:159-69
Huober J, Thürlimann Beat, Gelber R D, Colleoni M, Coates A S, Goldhirsch A, Price K N, Wardley A, Smith I, Láng I, Neven P, Forbes J F, Bonnefoi H, Ejlertsen B, Wu J, Giobbie-Hurder A, Rabaglio M, Cole B F, BIG 1-98 Collaborative and International Breast Cancer Study Groups
Reply: 'Comment on Anti-tumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer'
Omlin A, de Bono J, Van As N, Parker C, Dearnaley D, Sandhu S, Ferraldeschi R, Bianchini D, Mukherji D, Lorente D, Zaidi S, Pezaro C, Attard G. Reply: 'Comment on Anti-tumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer'. Br J Cancer 2013; 110:267-8.
03.12.2013Reply: 'Comment on Anti-tumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer'
03.12.2013Br J Cancer 2013; 110:267-8
Omlin Aurelius, de Bono J S, Van As N, Parker C, Dearnaley D, Sandhu S, Ferraldeschi R, Bianchini D, Mukherji D, Lorente D, Zaidi S, Pezaro C J, Attard G
Spiritual Experiences of Transcendence in Patients With Advanced Cancer
Renz M, Mao S, Omlin A, Büche D, Cerny T, Strasser F. Spiritual Experiences of Transcendence in Patients With Advanced Cancer. Am J Hosp Palliat Care 2013
02.12.2013Spiritual Experiences of Transcendence in Patients With Advanced Cancer
02.12.2013Am J Hosp Palliat Care 2013
Renz Monika, Mao Schuett M, Omlin Aurelius, Büche Daniel, Cerny Thomas, Strasser Florian
Attenuated expression of apoptosis stimulating protein of p53-2 (ASPP2) in human acute leukemia is associated with therapy failure
Schittenhelm M, Illing B, Ahmut F, Rasp K, Blumenstock G, Döhner K, Lopez C, Kampa-Schittenhelm K. Attenuated expression of apoptosis stimulating protein of p53-2 (ASPP2) in human acute leukemia is associated with therapy failure. PloS one 2013; 8:e80193.
27.11.2013Attenuated expression of apoptosis stimulating protein of p53-2 (ASPP2) in human acute leukemia is associated with therapy failure
27.11.2013PloS one 2013; 8:e80193
Schittenhelm Marcus, Illing Barbara, Ahmut Figen, Rasp Katharina Henriette, Blumenstock Gunnar, Döhner Konstanze, Lopez Charles D, Kampa-Schittenhelm Kerstin
Sterben als Übergangsprozess
Renz M (2013). Sterben als Übergangsprozess. Präsentiert bei: Palliative Care: Knowing More, Understanding Better, Inselspital Bern
26.11.2013Sterben als Übergangsprozess
26.11.2013Palliative Care: Knowing More, Understanding Better
Renz Monika
Visceral Disease in Castration-resistant Prostate Cancer
Pezaro C, de Bono J, Tunariu N, Crespo M, Altavilla A, Riisnaes R, Mukherji D, Bianchini D, Ferraldeschi R, Nava Rodrigues D, Lorente D, Omlin A, Attard G. Visceral Disease in Castration-resistant Prostate Cancer. Eur Urol 2013; 65:270-3.
22.11.2013Visceral Disease in Castration-resistant Prostate Cancer
22.11.2013Eur Urol 2013; 65:270-3
Pezaro Carmel J, de Bono Johann S, Tunariu Nina, Crespo Mateus, Altavilla Amelia, Riisnaes Ruth, Mukherji Deborah, Bianchini Diletta, Ferraldeschi Roberta, Nava Rodrigues Daniel, Lorente David, Omlin Aurelius, Attard Gerhardt
Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis
Vera-Badillo F, Ocana A, Tannock I, Seruga B, Al-Mubarak M, Bedard P, Diaz-Padilla I, de Gouveia P, Templeton A, Amir E. Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis. J Natl Cancer Inst 2013; 106:djt319.
22.11.2013Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis
22.11.2013J Natl Cancer Inst 2013; 106:djt319
Vera-Badillo Francisco E, Ocana Alberto, Tannock Ian F, Seruga Bostjan, Al-Mubarak Mustafa, Bedard Philippe L, Diaz-Padilla Ivan, de Gouveia Paulo, Templeton Arnoud, Amir Eitan
Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro)
von Minckwitz G, Costa S, Jackisch C, Paepke S, Schneeweiss A, Kümmel S, Denkert C, Mehta K, Loibl S, Blohmer J, Hanusch C, Rezai M, Fasching P, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, Untch M. Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro). Ann Oncol 2013; 25:81-9.
21.11.2013Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro)
21.11.2013Ann Oncol 2013; 25:81-9
von Minckwitz G, Costa S D, Jackisch C, Paepke S, Schneeweiss A, Kümmel S, Denkert C, Mehta K, Loibl S, Blohmer J U, Hanusch C, Rezai M, Fasching P A, Huober Jens, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, Untch M
Outcome of mantle cell lymphoma patients treated at a single institution over the past decade
Diem S. Outcome of mantle cell lymphoma patients treated at a single institution over the past decade. Hematological oncology 2013
16.11.2013Outcome of mantle cell lymphoma patients treated at a single institution over the past decade
16.11.2013Hematological oncology 2013
Diem Stefan
Diagnosis and treatment of mantle cell lymphoma
Hitz F, Bargetzi M, Cogliatti S, Lohri A, Taverna C, Renner C, Mey U. Diagnosis and treatment of mantle cell lymphoma. Swiss Med Wkly 2013; 143:w13868.
13.11.2013Diagnosis and treatment of mantle cell lymphoma
13.11.2013Swiss Med Wkly 2013; 143:w13868
Hitz Felicitas, Bargetzi Mario, Cogliatti Sergio, Lohri Andreas, Taverna Christian, Renner Christoph, Mey Ulrich
Baseline predictors of adherence to positive airway pressure therapy for sleep apnea: a 10-year single-center observational cohort study
Schoch O, Baty F, Niedermann J, Rüdiger J, Brutsche M. Baseline predictors of adherence to positive airway pressure therapy for sleep apnea: a 10-year single-center observational cohort study. Respiration 2013; 87:121-8.
05.11.2013Baseline predictors of adherence to positive airway pressure therapy for sleep apnea: a 10-year single-center observational cohort study
05.11.2013Respiration 2013; 87:121-8
Schoch Otto, Baty Florent, Niedermann Jolanda, Rüdiger Jochen, Brutsche Martin
Late term tolerance in head neck cancer patients irradiated in the IMRT era.
Studer G, Linsenmeier C, Riesterer O, Najafi Y, Brown M, Yousefi B, Bredell M, Huber G, Schmid S, Studer S, Zwahlen R, Rordorf T, Glanzmann C. Late term tolerance in head neck cancer patients irradiated in the IMRT era. Radiat Oncol 2013; 8:259.
05.11.2013Late term tolerance in head neck cancer patients irradiated in the IMRT era.
05.11.2013Radiat Oncol 2013; 8:259
Studer Gabriela, Linsenmeier Claudia, Riesterer Oliver, Najafi Yousef, Brown Michelle L, Yousefi Bita, Bredell Marius, Huber Gerhard, Schmid Stephan, Studer Stephan, Zwahlen Roger A, Rordorf Tamara, Glanzmann Christoph
Regulation of Endothelial Permeability in the Corpus Luteum: A Review of the Literature
Herr D, Bekes I, Wulff C. Regulation of Endothelial Permeability in the Corpus Luteum: A Review of the Literature. Geburtshilfe Frauenheilkd 2013; 73:1107-1111.
01.11.2013Regulation of Endothelial Permeability in the Corpus Luteum: A Review of the Literature
01.11.2013Geburtshilfe Frauenheilkd 2013; 73:1107-1111
Herr D, Bekes Inga, Wulff C
Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction
Jörger M, Huitema A, Koeberle D, Rosing H, Beijnen J, Hitz F, Cerny T, Schellens J, Gillessen Sommer S. Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction. Cancer Chemother Pharmacol 2013; 73:113-24.
29.10.2013Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction
29.10.2013Cancer Chemother Pharmacol 2013; 73:113-24
Jörger Markus, Huitema A D R, Koeberle D, Rosing H, Beijnen J H, Hitz Felicitas, Cerny Thomas, Schellens J H M, Gillessen Sommer Silke
First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer
Bianchini D, de Bono J, Scher H, Attard G, Rathkopf D, Buchbinder A, Zivi A, Riisnaes R, Miranda S, Figueiredo I, Crespo M, Mukherji D, Ferraldeschi R, Lorente D, Pezaro C, Omlin A, Danila D. First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer. Br J Cancer 2013; 109:2579-86.
29.10.2013First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer
29.10.2013Br J Cancer 2013; 109:2579-86
Bianchini D, de Bono J, Scher H I, Attard G, Rathkopf D E, Buchbinder A, Zivi A, Riisnaes R, Miranda S, Figueiredo I, Crespo M, Mukherji D, Ferraldeschi R, Lorente D, Pezaro C, Omlin Aurelius, Danila D C